World's Best Scientists 2026 revealed!

D-Index & Metrics

Discipline name D-Index World Ranking Current World Ranking National Ranking Current National Ranking Publications Citations
Medicine 91 11744 11048 451 437 416 30643

Stefan Suciu publications per year

The chart shows the history of publications by Stefan Suciu between 1982 and 2025, highlighting the no. of papers published in each year and offering an overview of the publication velocity of this scholar. Stefan Suciu published across 44 years, from 1982 to 2025, averaging 9.6 papers a year. Output peaked at 22 publications in 2014. 9 of the 421 publications appeared in the last two years.

No. of publications
5 10 15 20
Bar chart. Horizontal axis: year, 1982 to 2025. Vertical axis: number of publications, 0 to 22. Peak 22 publications in 2014. 1982: 1 publication 1983: 4 publications 1984: 5 publications 1985: 0 publications 1986: 7 publications 1987: 6 publications 1988: 8 publications 1989: 10 publications 1990: 12 publications 1991: 4 publications 1992: 9 publications 1993: 6 publications 1994: 6 publications 1995: 3 publications 1996: 9 publications 1997: 11 publications 1998: 7 publications 1999: 5 publications 2000: 8 publications 2001: 15 publications 2002: 8 publications 2003: 9 publications 2004: 14 publications 2005: 12 publications 2006: 7 publications 2007: 20 publications 2008: 13 publications 2009: 13 publications 2010: 12 publications 2011: 15 publications 2012: 20 publications 2013: 16 publications 2014: 22 publications 2015: 10 publications 2016: 17 publications 2017: 10 publications 2018: 13 publications 2019: 11 publications 2020: 16 publications 2021: 9 publications 2022: 6 publications 2023: 3 publications 2024: 7 publications 2025: 2 publications
1982 2025

421 publications in total across all disciplines

View publications per year as a table
Stefan Suciu: publications per year, 1982 to 2025
Year Publications
1982 1
1983 4
1984 5
1985 0
1986 7
1987 6
1988 8
1989 10
1990 12
1991 4
1992 9
1993 6
1994 6
1995 3
1996 9
1997 11
1998 7
1999 5
2000 8
2001 15
2002 8
2003 9
2004 14
2005 12
2006 7
2007 20
2008 13
2009 13
2010 12
2011 15
2012 20
2013 16
2014 22
2015 10
2016 17
2017 10
2018 13
2019 11
2020 16
2021 9
2022 6
2023 3
2024 7
2025 2
Total 421
Download as CSV

Stefan Suciu publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Stefan Suciu sits on this spectrum.

No. of scientists
200 400 600 800
Bar chart with 86 bars. Horizontal axis: publications, 101–120 to 1,796+. Vertical axis: number of scientists, 0 to 922. Most scientists, 922, have 341–360 publications. The last bar groups every scientist with 1,796 publications or more. The highlighted bar, 401–420 publications, is where this scientist sits. 101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101–120 publications 1,796+

This scientist: 416 publications — 42nd percentile

42% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

View publications distribution as a table
Number of Medicine scientists by publication count, Research.com 2026 ranking edition. Based on 20,134 ranked scientists.
Publications Scientists This scientist
101–120 5
121–140 26
141–160 73
161–180 155
181–200 230
201–220 363
221–240 487
241–260 545
261–280 722
281–300 768
301–320 834
321–340 895
341–360 922
361–380 838
381–400 861
401–420 918 416
421–440 806
441–460 771
461–480 751
481–500 713
501–520 617
521–540 610
541–560 537
561–580 504
581–600 509
601–620 396
621–640 386
641–660 371
661–680 340
681–700 336
701–720 307
721–740 259
741–760 230
761–780 228
781–800 217
801–820 204
821–840 186
841–860 177
861–880 155
881–900 139
901–920 145
921–940 116
941–960 133
961–980 91
981–1,000 96
1,001–1,020 77
1,021–1,040 70
1,041–1,060 63
1,061–1,080 77
1,081–1,100 49
1,101–1,120 54
1,121–1,140 49
1,141–1,160 51
1,161–1,180 35
1,181–1,200 39
1,201–1,220 26
1,221–1,240 37
1,241–1,260 36
1,261–1,280 27
1,281–1,300 32
1,301–1,320 28
1,321–1,340 17
1,341–1,360 30
1,361–1,380 28
1,381–1,400 17
1,401–1,420 21
1,421–1,440 15
1,441–1,460 12
1,461–1,480 12
1,481–1,500 18
1,501–1,520 14
1,521–1,540 17
1,541–1,560 15
1,561–1,580 6
1,581–1,600 2
1,601–1,620 12
1,621–1,640 11
1,641–1,660 8
1,661–1,680 5
1,681–1,700 5
1,701–1,720 10
1,721–1,740 12
1,741–1,760 14
1,761–1,780 6
1,781–1,795 5
1,796+ 100
Download as CSV

Stefan Suciu D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Stefan Suciu sits on this spectrum.

No. of scientists
250 500 750 1,000
Bar chart with 75 bars. Horizontal axis: D-Index, 70–71 to 217+. Vertical axis: number of scientists, 0 to 1,027. Most scientists, 1,027, have 82–83 D-Index. The last bar groups every scientist with 217 D-Index or more. The highlighted bar, 90–91 D-Index, is where this scientist sits. 70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70–71 D-Index 217+

This scientist: 91 D-Index — 43rd percentile

43% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

View D-Index distribution as a table
Number of Medicine scientists by D-index, Research.com 2026 ranking edition. Based on 20,134 ranked scientists.
D-Index Scientists This scientist
70–71 226
72–73 391
74–75 574
76–77 730
78–79 891
80–81 972
82–83 1,027
84–85 1,003
86–87 960
88–89 970
90–91 922 91
92–93 839
94–95 808
96–97 779
98–99 668
100–101 611
102–103 630
104–105 513
106–107 541
108–109 445
110–111 429
112–113 399
114–115 393
116–117 318
118–119 302
120–121 287
122–123 255
124–125 256
126–127 252
128–129 230
130–131 179
132–133 168
134–135 163
136–137 159
138–139 134
140–141 134
142–143 118
144–145 109
146–147 106
148–149 74
150–151 79
152–153 80
154–155 87
156–157 57
158–159 74
160–161 69
162–163 60
164–165 53
166–167 39
168–169 42
170–171 32
172–173 39
174–175 40
176–177 28
178–179 19
180–181 23
182–183 31
184–185 18
186–187 20
188–189 22
190–191 13
192–193 21
194–195 12
196–197 12
198–199 14
200–201 15
202–203 13
204–205 10
206–207 8
208–209 4
210–211 12
212–213 11
214–215 10
216 4
217+ 98
Download as CSV

Overview

Stefan Suciu is affiliated with the European Organisation for Research and Treatment of Cancer in the Netherlands. Their primary field of study is Medicine, with a focus on Oncology. Additional subfields of research include Public Health, Environmental and Occupational Health, Hematology, Pediatrics, Perinatology and Child Health, and Molecular Biology.

Research topics covered by Stefan Suciu's work include:

  • Cutaneous Melanoma Detection and Management
  • Cancer Immunotherapy and Biomarkers
  • Acute Lymphoblastic Leukemia research
  • CAR-T cell therapy research
  • Childhood Cancer Survivors' Quality of Life
  • Melanoma and MAPK Pathways
  • Acute Myeloid Leukemia Research

Frequent coauthors collaborating with Suciu are:

  • Michal Kiciński
  • Alexander M.M. Eggermont
  • Caroline Robert
  • Christian U. Blank
  • Mario Mandalà

Publications have appeared in various scientific journals, with multiple contributions in these venues:

  • European Journal of Cancer
  • Journal of Clinical Oncology
  • The Lancet Oncology
  • American Journal of Hematology
  • JAMA Oncology

Recent papers authored or coauthored by Stefan Suciu include:

  • Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo, 2020, JAMA Oncology
  • Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial, 2021, The Lancet Oncology
  • Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial, 2020, Journal of Clinical Oncology
  • Five-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III Melanoma, 2022, NEJM Evidence
  • Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial, 2021, The Lancet Oncology

Best Publications

  • Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

    Alexander M.M. Eggermont;Christian U. Blank;Mario Mandala;Georgina V. Long

  • Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy

    Alexander M M Eggermont;Vanna Chiarion-Sileni;Jean-Jacques Grob;Reinhard Dummer

  • Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial

    Alexander M M Eggermont;Vanna Chiarion-Sileni;Jean Jacques Grob;Reinhard Dummer

  • Autologous or Allogeneic Bone Marrow Transplantation Compared with Intensive Chemotherapy in Acute Myelogenous Leukemia

    R. A. Zittoun;F. Mandelli;R. Willemze;T. De Witte

  • Clinical Significance of Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia

    Cavé H;van der Werff ten Bosch J;Suciu S;Guidal C

  • Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial.

    Alexander M. M. Eggermont;Stefan Suciu;Mario Santinami;Alessandro Testori

  • Low-Dose Decitabine Versus Best Supportive Care in Elderly Patients With Intermediate- or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group

    Michael Lübbert;Stefan Suciu;Liliana Baila;Björn Hans Rüter

  • Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer-Children's Leukemia Group phase 3 trial.

    Michel Duval;Stefan Suciu;Alina Ferster;Xavier Rialland

  • On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group.

    B Löwenberg;R Zittoun;H Kerkhofs;U Jehn

  • Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial

    Stefan Suciu;Franco Mandelli;Theo de Witte;Robert Zittoun

  • Predictive Gene Signature in MAGE-A3 Antigen-Specific Cancer Immunotherapy

    Fernando Ulloa-Montoya;Jamila Louahed;Benjamin Dizier;Olivier Gruselle

  • Modulation of multidrug-resistant multiple myeloma by cyclosporin

    P Sonneveld;B Lowenberg;B.G.M Durie;H.M Lokhorst

  • Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials

    Keith Wheatley;Natalie Ives;Barry Hancock;Martin Gore

  • Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group.

    B. Löwenberg;S. Suciu;E. Archimbaud;H. Haak

  • Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial

    Sergio Amadori;Stefan Suciu;Dominik Selleslag;Franco Aversa

  • Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial.

    Alexander M. M. Eggermont;Stefan Suciu;Rona Mackie;Wlodzimierz Ruka

  • Expression of MAGE genes in primary and metastatic cutaneous melanoma.

    Francis Brasseur;Donata Rimoldi;Danielle Liénard;Danielle Liénard;Bernard Lethé

  • Use of recombinant granulocyte-macrophage colony-stimulating factor during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia (AML): final report of AML-11, a phase III randomized study of the Leukemia Cooperative Group of European Organisation for the research and treatment of cancer (EORTC-LCG) and the Dutch Belgian Hemato-Oncology Cooperative Group (HOVON)

    B. Lowenberg;S. Suciu;E. Archimbaud;G.J. Ossenkoppele

  • Long-Term Results of the Randomized Phase III Trial EORTC 18991 of Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III Melanoma

    Alexander M.M. Eggermont;Stefan Suciu;Alessandro Testori;Mario Santinami

Frequent Co-Authors

Alexander M.M. Eggermont
Alexander M.M. Eggermont Institut Gustave Roussy
Theo de Witte
Theo de Witte Radboud University
Sergio Amadori
Sergio Amadori University of Rome Tor Vergata
Hélène Cavé
Hélène Cavé Université Paris Cité
Caroline Robert
Caroline Robert University of Paris-Saclay
Ulrich Keilholz
Ulrich Keilholz Charité - University Medicine Berlin
Franco Mandelli
Franco Mandelli Sapienza University of Rome
Dirk Schadendorf
Dirk Schadendorf University of Duisburg-Essen
Frédéric Baron
Frédéric Baron University of Liège
Reinhard Dummer
Reinhard Dummer University of Zurich

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those considering medical careers beyond the traditional MD route, a range of online degrees and programs can open doors to in-demand health professions. Prospective nurses can benefit from the rn to bsn online cost guide to find flexible and cost-effective pathways to advance from a registered nurse to a Bachelor of Science in Nursing. This progression can lead to better job opportunities and higher salaries.

If you do not already have a nursing background, there are direct entry nurse practitioner programs for non-nurses online available. These programs allow graduates from other fields to enter advanced practice nursing rapidly. Additionally, for those looking for accessible programs, many online bsn programs for non nurses are designed to help you start your nursing journey without traditional barriers.

For students who are interested in the healthcare industry but not in direct patient care, medical administration may be a good fit. Explore medical billing and coding financial aid programs, which provide entry into this essential and flexible field, often with financial assistance options.

Best Scientists Citing Stefan Suciu

Trending Scientists

Recently Published Articles